2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Genitourinary
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Lung Cancer Metastatic
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
1174
Cisplatin
891
Pemetrexed
847
pembrolizumab
626
Paclitaxel
609
Docetaxel
539
Gemcitabine
428
Radiotherapy
393
Erlotinib Hydrochloride
381
Nivolumab
344
Bevacizumab
337
Etoposide
297
durvalumab
264
Drug Therapy
260
osimertinib
237
atezolizumab
225
Radiosurgery
196
Gefitinib
186
Vinorelbine
149
Magnetic Resonance Spectroscopy
132
Ipilimumab
129
130-nm albumin-bound paclitaxel
125
Cetuximab
113
Blood Specimen Collection
106
anlotinib
105
tislelizumab
103
Topotecan
103
Specimen Handling
102
Surgical Procedures, Operative
101
Cyclophosphamide
101
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
evolocumab
×
Thoracic
×
Clear all
NCT03337698
2026-05-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2
Terminated
314 enrolled
31 charts
NCT05144529
2026-05-05
TOP2101
Duke University
Phase 2
Terminated
19 enrolled
16 charts